Last reviewed · How we verify
GSK2269557 100 MCG — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK2269557 100 MCG (GSK2269557 100 MCG) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK2269557 100 MCG TARGET | GSK2269557 100 MCG | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK2269557 100 MCG CI watch — RSS
- GSK2269557 100 MCG CI watch — Atom
- GSK2269557 100 MCG CI watch — JSON
- GSK2269557 100 MCG alone — RSS
Cite this brief
Drug Landscape (2026). GSK2269557 100 MCG — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2269557-100-mcg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab